Scil Proteins Establishes Business Development Infrastructure in North America

Scil Proteins Establishes Business Development Infrastructure in North America
Appoints Garry Merry as Business Development Consultant

Halle, Germany, 14th March 2012- Scil Proteins, a private biotech company specialized in research, development and production of recombinant proteins, today announced that it has established a California-based Business Development organization in direct response to the ever-increasing demand for the Company's protein production services in North America. The organization will provide local business support for the Company's US and Canadian CMO customers.

Scil Proteins is delighted to announce that it has appointed Garry Merry to lead this new organization. Mr. Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies GmbH, Isogenica Ltd. and TerraSep LLC. Mr. Merry has also held senior executive positions at several leading life science companies, including Waters, Applied Biosystems and Qiagen.

"A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis," said Frank Ubags, COO of Scil Proteins. "With his background in protein engineering and separations, Garry Merry is ideally positioned to help us achieve our growth objectives."

Commenting on his appointment, Garry Merry added, "My career has always revolved around proteins, going back as far back as 1986, when I helped found the Protein Society. That being said, I am pleased that Scil Proteins has asked me to support their business efforts here in North America and I am confident that the Company's world-class GMP facility in Germany will be extremely busy going forward."

Scil Proteins' powerful Affilin® drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the Company's corporate headquarter in Halle, Germany. In addition, Scil Proteins' corporate headquarters will remain responsible for all other activities related to the Company's CMO business outside of the US and Canada.